Tirzepatide vs Semaglutide

The core difference is mechanical. Tirzepatide is a single molecule that activates two gut-hormone receptors at once (GIP and GLP-1), while semaglutide activates just one (GLP-1). In placebo-controlled and head-to-head trials the dual-agonist tirzepatide has produced the larger average weight reduction, whereas semaglutide has the longer real-world track record and a lower entry price. For a South African research buyer, tirzepatide suits protocols prioritising the largest modelled effect, and semaglutide suits those wanting a lower-cost, exhaustively characterised single-pathway comparator.

Both are stocked at BeSkinny as research-grade peptides in the weight-loss injections range. This guide compares mechanism, published trial evidence, side-effect reporting, formats and price so you can specify the right compound. Everything below is framed for laboratory and research use, not human treatment.

Tirzepatide vs semaglutide at a glance

The table condenses the practical differences. Figures describe what the peer-reviewed obesity trials and manufacturer product labels report; they are not outcomes you should expect or a dosing protocol.

Attribute	Tirzepatide	Semaglutide
Mechanism	Dual agonist — activates both the GIP and the GLP-1 receptor in one molecule	Single agonist — activates the GLP-1 receptor only
Trial weight-loss (mean)	About 15% to 21% at 72 weeks across doses (SURMOUNT-1); superior to semaglutide in the direct head-to-head (SURMOUNT-5)	About 15% at 68 weeks (STEP-1)
Research dose cadence	Once weekly, titrated upward over several weeks	Once weekly, titrated upward over several weeks
Formats stocked	Lyophilised vial and pre-filled pen (30 mg and 60 mg)	Lyophilised vial and pre-filled pen (6 mg to 10 mg)
Reconstitution needed	Vial: yes (add bacteriostatic water). Pen: no	Vial: yes (add bacteriostatic water). Pen: no
Side-effect profile	GI-predominant (nausea, diarrhoea, vomiting, constipation)	GI-predominant (nausea, diarrhoea, vomiting, constipation)
Price at BeSkinny (ZAR)	From about R1800 (vial); pens from about R2100	From about R1400 (vial); pens from about R1600

What each molecule is

Tirzepatide: the dual GIP/GLP-1 agonist

Tirzepatide is a synthetic peptide engineered to bind two incretin receptors: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). Combining both actions in one molecule is the defining feature and the reason it is described as a dual agonist or twincretin. In research models the twin action is associated with stronger effects on appetite signalling and glucose handling than single-receptor agonists. You can review the compound and stocked strengths on the tirzepatide category hub, with the flagship HD Labs Tirzepatide 30 vial as the entry SKU.

Semaglutide: the single GLP-1 agonist

Semaglutide is a GLP-1 receptor agonist — it mimics the GLP-1 incretin hormone alone. It is the more established of the two molecules, with a deeper and longer body of published data behind it. That maturity makes it the standard single-pathway reference point against which newer agonists are measured. See the semaglutide category hub and the HD Labs Semaglutide 10 vial for stocked options.

Efficacy: what the trials report

Head-to-head and placebo-controlled trials are the fairest basis for comparison. The numbers below are approximate means drawn from the published papers; individual studies used different doses, durations and statistical estimands, so treat them as directional.

• Tirzepatide in obesity (SURMOUNT-1, NEJM 2022). Over 72 weeks, mean body-weight reduction ranged from roughly 15% at the lower dose to about 21% at the top dose, with one trial estimand reporting up to about 22.5%, versus roughly 2% to 3% on placebo.
• Semaglutide in obesity (STEP-1, NEJM 2021). Over 68 weeks, mean body-weight reduction was about 15% (reported as roughly minus 14.9%) versus about minus 2.4% on placebo.
• Direct head-to-head (SURMOUNT-5, NEJM 2025). At 72 weeks tirzepatide produced a larger mean reduction (about 20%) than semaglutide (about 14%) in the same trial — the clearest single comparison of the two.
• Tirzepatide in type 2 diabetes (SURPASS programme, Lancet and NEJM). The SURPASS trials reported large reductions in HbA1c alongside weight loss, and SURPASS-2 found tirzepatide superior to semaglutide on both glucose control and weight in that population.

The consistent pattern is that the dual agonist shows the larger average effect, while semaglutide remains a strong, well-documented performer. Because these are group averages from clinical populations, they describe trends in the evidence base, not a promised result for any research protocol.

Side effects: what trials and labels report

By research convention we describe adverse events as they appear in the trial publications and product labels, not as medical advice. For both molecules the dominant category is gastrointestinal: nausea, diarrhoea, vomiting and constipation, most often mild to moderate and most common during dose escalation. Because tirzepatide and semaglutide share the GLP-1 pathway, their side-effect character is broadly similar in class. In the SURMOUNT-5 head-to-head the two showed comparable overall tolerability, with GI events the leading reason for reported discomfort in each arm. Slower titration is the commonly cited way trials managed these effects.

Formats and how to buy in South Africa

BeSkinny stocks both molecules in two research formats, and the choice affects handling more than anything else.

• Vials (lyophilised powder). The lowest-cost route. A vial must be reconstituted with bacteriostatic water before use; our peptide reconstitution calculator works out the water volume and draw for a target concentration. Tirzepatide starts with the HD Labs Tirzepatide 30 vial (about R1800); semaglutide with the HD Labs Semaglutide 10 vial (about R1400).
• Pre-filled pens. Supplied ready-mixed, so no reconstitution and no separate bacteriostatic water. Convenience carries a premium — tirzepatide pens run from about R2100 (and up to about R3500 for the larger Body Pharm 60 mg pen), semaglutide pens from about R1600.

Both molecules are temperature-sensitive, so BeSkinny ships them cold-chain with gel packs to preserve integrity in transit across South Africa. Payment is by EFT, card or Bitcoin, and placing an order requires a verified BeSkinny account. Browse everything side by side on the weight-loss injections hub. Prices drift with stock and supplier costs, so treat the figures here as approximate starting points and check the live product pages.

Which one to choose

The decision usually comes down to the effect-versus-cost trade-off and how established you want the evidence base to be.

• Consider tirzepatide if your protocol prioritises the largest average effect reported in trials, you want the dual GIP/GLP-1 mechanism, and the higher price and pen premium are acceptable.
• Consider semaglutide if you want the longer, deeper documentation of a single-pathway GLP-1 agonist, a lower entry cost, or a well-characterised reference comparator for benchmarking.
• Consider the vial over the pen when cost is the priority and you are comfortable reconstituting; choose the pen when you want a ready-mixed format and will pay for the convenience.

If you are mapping the whole agonist landscape, the emerging retatrutide triple-agonist (GIP, GLP-1 and glucagon) sits one step beyond tirzepatide and is worth noting as the next-generation option, though its evidence base is younger than either molecule here.

Research-use disclaimer

All products discussed are supplied strictly for laboratory and research purposes. Nothing on this page is medical advice, a treatment recommendation, or a human dosing protocol. The efficacy and safety figures describe what published clinical trials and manufacturer product labels report, cited following standard research-reference convention. BeSkinny supplies the molecules tirzepatide and semaglutide as research compounds; it does not sell branded consumer medicines.

Frequently asked questions

Is tirzepatide stronger than semaglutide?

On trial averages, yes. In the direct SURMOUNT-5 head-to-head, tirzepatide produced a larger mean weight reduction than semaglutide, and its obesity trial (SURMOUNT-1) reported higher figures than semaglutide's (STEP-1). The dual GIP/GLP-1 mechanism is the usual explanation. "Stronger" also tends to mean a stronger dose of the same GI effects, so tolerability matters too.

Can you switch between semaglutide and tirzepatide?

Research protocols do sometimes model a transition between the two. Because both act on the GLP-1 pathway, titration is generally restarted at a low level to manage gastrointestinal tolerance rather than matching dose-for-dose. This is a description of how studies handle it, not a personal instruction.

Which has fewer side effects?

Both are GI-predominant and broadly comparable in class, since they share the GLP-1 pathway. The SURMOUNT-5 head-to-head reported similar overall tolerability, with nausea and other GI events leading in each arm. Effects are most common during dose escalation and typically mild to moderate.

Do I need to reconstitute a vial or a pen?

Vials arrive as a lyophilised powder and must be reconstituted with bacteriostatic water before use — the reconstitution calculator handles the maths. Pre-filled pens come ready-mixed, so no reconstitution is required.

Which is cheaper at BeSkinny?

Semaglutide is the lower-cost entry point, starting from about R1400 for the HD Labs Semaglutide 10 vial versus about R1800 for the HD Labs Tirzepatide 30 vial. Pens cost more than vials in both molecules because they are supplied ready-mixed. Prices are approximate and can drift.

Sources

• Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216. PubMed
• Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1). N Engl J Med. 2021;384:989-1002. NEJM
• Frias JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. 2021;385:503-515. NEJM
• Rosenstock J, et al. Efficacy and safety of the dual GIP and GLP-1 receptor agonist tirzepatide in type 2 diabetes (SURPASS-1). Lancet. 2021;398:143-155. The Lancet
• Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med. 2025. Summary via American College of Cardiology
• Drugs.com drug monographs: tirzepatide and semaglutide
• Manufacturer prescribing information (product labels) via Drugs@FDA